A promising solution to a cancer drug resistance problem
- Details
- Category: Research
A protein that can dial down oxidative stress in cells helps some cancers resist treatment with a widely used class of drugs called BTK inhibitors, according to a study led by investigators at Weill Cornell Medicine. The discovery points to a possible solution to the problem of BTK inhibitor treatment resistance.
BTK inhibitors reduce the activity of the enzyme BTK (Bruton’s Tyrosine Kinase), which has a central role in immune cells called B cells.
Viagra may reduce cancer metastasis
- Details
- Category: Research
Viagra was originally developed to treat high blood pressure and chest pain caused by reduced blood flow to the heart, but over the past three decades it has become the world’s best-known therapy for erectile dysfunction. In the future, this blockbuster drug may find yet another use. In a study published recently in Cancer Research, scientists in the lab of Prof. Ayelet Erez at the Weizmann Institute of Science found that sildenafil, Viagra’s active ingredient, may restrict cancer metastasis through a newly discovered biological mechanism.
New approach to the development of non-opioid painkillers
- Details
- Category: Research
An international research team led by the Medical University of Vienna has investigated a new peptide derived from cone snail venom which significantly reduced inflammation-induced pain in an animal model. Crucially, its effect takes hold immediately after subcutaneous injection, whereas previously known cone snail peptides must be administered directly into the cerebrospinal fluid.
More than half of U.S. adults now eligible for statins under new guidelines
- Details
- Category: Research
More than half of U.S. adults ages 30 to 79 - about 87.5 million people - are now recommended for statins to prevent cardiovascular disease under newly updated clinical guidelines, according to a study by University of Pittsburgh School of Medicine researchers published in JAMA.
The new recommendations significantly change how doctors assess cardiovascular risk by looking beyond the next 10 years to a person’s risk over several decades.
Many countries overusing powerful antibiotics
- Details
- Category: Research
Many countries are using too many powerful and inappropriate antibiotics, fuelling antibiotic resistance concerns, while millions lack access to the specific drugs they need. That is according to a major international study of antibiotic use published in The Lancet Public Health.
Research led by City St George's, University of London and University of Oxford developed the first global framework that estimates how many and which type of antibiotics each country needs to treat their infections.
GLP-1 diabetes drugs linked to increased risk of hair loss
- Details
- Category: Research
Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, finds a study published by The BMJ.
Although the absolute risk is low, awareness of this potential effect may help to inform shared treatment decisions, say the researchers.
Study reveals structure of brain protein and identifies potential drug target for epilepsy research
- Details
- Category: Research
Scientists at the Icahn School of Medicine at Mount Sinai have uncovered the first high-resolution structure of NBCn2, a brain protein linked to epilepsy, autism spectrum disorder, and other neurological conditions, and developed the first compounds capable of inhibiting its activity. The findings provide a new framework for studying how altered brain signaling contributes to disease and may help advance future therapeutic research.
More Pharma News ...
- A secret weapon against superbugs
- Researchers clear two major hurdles for minimally invasive cancer therapy
- AI platform could speed peptide drug discovery
- Starving bacteria to death
- Cutting-edge drug shows promise for patients with NRAS-driven melanoma
- Development of a novel "degraders" for the selective elimination of cancer cells
- RAS inhibitor daraxonrasib demonstrates initial anti-tumor activity in pancreatic cancer